BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9454657)

  • 21. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
    Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
    Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
    Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
    Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
    Hayashi M; Shibazaki M; Sohma R; Inaba N
    Am J Med Sci; 2006 Oct; 332(4):181-5. PubMed ID: 17031243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Selected hematopoietic cytokines in patients with colorectal cancer].
    Mroczko B; Ławicki S; Szmitkowski M; Czygier M; Okulczyk B; Piotrowski Z
    Pol Merkur Lekarski; 2003 Nov; 15(89):416-9. PubMed ID: 14969133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
    Kataoka T; Watanabe Y; Hoshiai H
    J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
    Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
    Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating macrophage colony-stimulating factor is not reduced in malignant osteopetrosis.
    Orchard PJ; Dahl N; Aukerman SL; Blazar BR; Key LL
    Exp Hematol; 1992 Jan; 20(1):103-5. PubMed ID: 1577090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis].
    Xu KF; Chen Y; Guo ZJ; Zhu YJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):824-8. PubMed ID: 15730782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of macrophage colony-stimulating factor in trophoblastic disease.
    Kohorn EI; Kacinski BM; Stanley ER
    Gynecol Oncol; 2001 Mar; 80(3):383-6. PubMed ID: 11263936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Fuith LC; Czarnecki M; Wachter H; Fuchs D
    Obstet Gynecol; 1994 May; 83(5 Pt 1):801. PubMed ID: 8164949
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased levels of serum macrophage colony-stimulating factor before the onset of preeclampsia.
    Hayashi M; Ohkura T; Inaba N
    Horm Metab Res; 2003 Oct; 35(10):588-92. PubMed ID: 14605992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new serological diagnostic method for malignant ovarian tumors of germ cell origin. Detection of antibodies to large glycopeptides isolated from F9 cells].
    Higaki K; Kawata M; Sekiya S; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 Dec; 35(12):2274-82. PubMed ID: 6663135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
    Suzuki M; Ohwada M; Sato I; Nagatomo M
    Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Measurement of macrophage colony-stimulating factor during in-vitro fertilization and embryo transfer cycles].
    Quan S; Wan L; Song L
    Zhonghua Fu Chan Ke Za Zhi; 2000 Jan; 35(1):42-4. PubMed ID: 11831950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of serum VEGF in women with ovarian tumors.
    Oehler MK; Caffier H
    Anticancer Res; 1999; 19(4A):2519-22. PubMed ID: 10470186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.